My Toolbox    |   Contact Us   |   Help    |   Sign In       

Home   |   Programs & Loans   |   Resources   |   Glossary   |   FAQs

  

Don't have an Account? Sign Up . It's Free

 Sign In to Your Account

E-mail Address* Password*
Forgot your Password?           * Required fields
    

 Why Sign Up for an Account?

Our tools will help you create a personalized business plan and financial statements. And all of it is free for everyone!

Business Plan

Use our easy, step-by-step form to generate your business plan. You can even use our sample business plan as a helpful guide.

Financial Reports

Answer the questions in our three step interview process and you will immediately be presented a Profit & Loss statement, and Cash Flow statement, and a Balance Sheet - all customized to your business.                               

Home

Sample Business Plan & Financial Reports

Your business plan is the road map for your business. It clearly defines your business, identifies your goals, and describes in detail where you are today, where you plan to be in the future, and how you are going to get there. Your business plan, like your business, is a living thing. No business remains static, the plan will need to be revisited periodically and updated to reflect changes in your business. Our website will save your plan for five years from the last time you visited it, unless you personally delete it. You can come back and edit it as often as you need.

View Sample


Industry News


FDA approves Epclusa for treatment of chronic Hepatitis C virus infection 6/28/2016
The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin. Epclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.
Federal Court orders California soy company to cease production due to food safety violations 6/28/2016
The U.S. District Court for the Eastern District of California entered a consent decree of permanent injunction on Friday, June 24, 2016, between the U.S. Food and Drug Administration and Wa Heng Dou-Fu & Soy Sauce Corporation requiring the business to immediately cease manufacturing and distributing food until it comes into compliance with federal food safety laws.
FDA approves AspireAssist obesity device 6/14/2016
The U.S. Food and Drug Administration today approved a new obesity treatment device that uses a surgically-placed tube to drain a portion of the stomach contents after every meal.
FDA approves vaccine to prevent cholera for travelers 6/10/2016
The U.S. Food and Drug Administration today approved Vaxchora, a vaccine for the prevention of cholera caused by serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas. Vaxchora is the only FDA-approved vaccine for the prevention of cholera.
FDA targets unlawful internet sales of illegal prescription medicines during International Operation Pangea IX 6/9/2016
The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, announced that it took action this week against 4,402 websites that illegally sell potentially dangerous, unapproved prescription drugs to U.S. consumers. This effort was part of Operation Pangea IX, the Ninth Annual International Internet Week of Action (IIWA), a global cooperative effort, led by INTERPOL, to combat the unlawful sale and distribution of illegal and potentially counterfeit medical products on the internet.
Statement on HHS OIG Early Alert on FDA food recall initiation process 6/9/2016
Public health is our top priority and the U.S. Food and Drug Administration works hard to ensure the U.S. food supply remains among the safest in the world.
Statement from FDA Commissioner Robert Califf, M.D. on the release of the final individual patient expanded access form 6/2/2016
Today, the U.S. Food and Drug Administration finalized its efforts to streamline the process used by physicians to request expanded access, often called “compassionate use,” to investigational drugs and biologics for their patients. As a physician, I understand the importance of being able to access investigational treatments for a patient when there are no other options to treat their serious disease or condition.
FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors 6/1/2016
The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs).
FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer 6/1/2016
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. Such mutations are present in approximately 10-20 percent of non-small cell lung cancers (NSCLC).
FDA takes action against Kansas food manufacturer for repeated food safety violations 6/1/2016
The U.S. District Court for the District of Kansas entered a consent decree of permanent injunction today between the United States and Native American Enterprises, LLC, located in Wichita, Kansas; its part-owner, William N. McGreevy; and its production manager, Robert C. Conner.
FDA issues draft guidance to food industry for voluntarily reducing sodium in processed and commercially prepared food 6/1/2016
Today, the U.S. Food and Drug Administration issued draft guidance for public comment that provides practical, voluntary sodium reduction targets for the food industry. Average sodium intake in the U.S. is approximately 3,400 mg/day. The draft short-term (two-year) and long-term (10-year) voluntary targets for industry are intended to help the American public gradually reduce sodium intake to 2,300 milligrams (mg) per day, a level recommended by leading experts and the overwhelming body of scientific evidence. The targets are also intended to complement many existing efforts by food manufacturers, restaurants, and food service operations to reduce sodium in foods.
FDA approves Ocaliva for rare, chronic liver disease 5/31/2016
Today the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA.
FDA approves Zinbryta to treat multiple sclerosis 5/27/2016
The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly.
FDA approves new diagnostic imaging agent to detect recurrent prostate cancer 5/27/2016
The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment.
FDA approves first buprenorphine implant for treatment of opioid dependence 5/26/2016
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
FDA issues final food defense regulation 5/26/2016
The U.S. Food and Drug Administration today finalized a new food safety rule under the landmark, bipartisan FDA Food Safety Modernization Act (FSMA) that will help to prevent wide-scale public health harm by requiring companies in the United States and abroad to take steps to prevent intentional adulteration of the food supply. While such acts are unlikely to occur, the new rule advances mitigation strategies to further protect the food supply.
FDA modernizes Nutrition Facts label for packaged foods 5/20/2016
FDA modernizes Nutrition Facts label for packaged foods
FDA approves new, targeted treatment for bladder cancer 5/18/2016
The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.
FDA issues rule for data collection of antimicrobial sales and distribution by animal species 5/10/2016
The U.S. Food and Drug Administration (FDA) finalized a rule today that revises its annual reporting requirements for drug sponsors of all antimicrobials sold or distributed for use in animals intended for human consumption or food-producing animals. Companies are now required to provide estimates of sales broken down by major food-producing species (cattle, swine, chickens and turkeys) in addition to the overall estimates they already submit on the amount of antimicrobial drugs they sell or distribute for use in food-producing animals.
FDA reminds health care professionals not to use drug products intended to be sterile from Medaus 5/5/2016
FDA reminds health care professionals not to use drug products intended to be sterile from Medaus

Loan Calculator
This is a quick way for you to find out how much it might cost you to buy that new piece of equipment or even a house. Simply enter your desired loan amount, term/period of loan and your estimated percentage rate to calculate your likely monthly payment.

 Loan  Amount: $*  
 Terms in  Months: *  
 Interest  Rate:*  %
 

 

* Required fields


Programs and Loans [more]
Our Business Plans and Financial Reports are designed to be taken to any bank or lender and there are many programs available in the agricultural industry. Find a program or lender that is right for you today.

Resources [more]
We have provided links to useful resources. Please click on "more" to access them. You may also access these links after you have logged in by clicking on Resources located at the top of each page.

 

Privacy Statement   |   Contact Us